Weekly Endocrinology Research Analysis
This week’s endocrinology literature highlights mechanistic, prognostic, and interventional advances. A Science Advances study uncovers a recurrent germline-to-somatic LOH mechanism that inactivates mitochondrial complex I (NDUFS1) and drives metabolic reprogramming in oncocytic thyroid carcinoma. JCI Insight reports a validated, treatment‑responsive plasma proteomic score that improves MACE risk prediction in diabetes and is modifiable by GLP‑1 receptor agonists. A Diabetes randomized human stu
Summary
This week’s endocrinology literature highlights mechanistic, prognostic, and interventional advances. A Science Advances study uncovers a recurrent germline-to-somatic LOH mechanism that inactivates mitochondrial complex I (NDUFS1) and drives metabolic reprogramming in oncocytic thyroid carcinoma. JCI Insight reports a validated, treatment‑responsive plasma proteomic score that improves MACE risk prediction in diabetes and is modifiable by GLP‑1 receptor agonists. A Diabetes randomized human study shows dietary medium‑chain triglyceride (MCT)–driven ketogenesis supports brain metabolism and preserves cognition during hypoglycemia in type 1 diabetes, suggesting a practical neuroprotective strategy.
Selected Articles
1. Loss of heterozygosity exposes germline mutations in complex I and drives Warburg metabolism in oncocytic carcinoma of the thyroid.
The authors establish an oncocytic thyroid carcinoma cell line (UT946) with severe complex I dysfunction and show that a nuclear-encoded NDUFS1 loss‑of‑function germline allele becomes pathogenic through tumor loss of heterozygosity. Reanalysis of 91 tumor genomes demonstrates LOH-driven exposure of recessive germline complex I mutations is a recurrent mechanism underpinning complex I inactivation and metabolic reprogramming in oncocytic thyroid carcinoma.
Impact: Uncovers a previously unrecognized germline-to-somatic mechanism (LOH exposing recessive NDUFS1 and other complex I variants) driving metabolic reprogramming in oncocytic thyroid carcinoma, reframing genetic counseling and pointing to mitochondrial complex I as a mechanistic and therapeutic vulnerability.
Clinical Implications: Suggests consideration of germline testing for complex I (including NDUFS1) in oncocytic thyroid carcinoma and motivates exploration of therapies exploiting complex I loss or synthetic lethal metabolic dependencies; informs tumor genetic counselling.
Key Findings
- Established UT946 oncocytic thyroid cancer cell line with profound complex I dysfunction and Warburg phenotype.
- Identified a nuclear-encoded NDUFS1 loss‑of‑function germline allele that became pathogenic via tumor LOH; reanalysis of 91 tumors shows this LOH-exposure mechanism is recurrent.
2. A Validated, Modifiable Proteomic Score from the EXSCEL Trial Predicts Cardiovascular Events in Diabetes.
Using baseline and 12‑month plasma proteomics from the randomized EXSCEL trial, investigators derived a supervised machine‑learning multi‑protein score that improved discrimination of MACE beyond clinical factors and validated it in independent cohorts. The score (and top proteins such as tetranectin) was modifiable by GLP‑1 receptor agonist treatment and decreases in the score associated with better outcomes, suggesting a treatment‑responsive prognostic biomarker.
Impact: Provides a generalizable, externally validated, and treatment‑responsive proteomic risk score—moving prognostication from static clinical models toward dynamic, modifiable biomarkers that can guide precision prevention and therapy monitoring in diabetes.
Clinical Implications: Could enable dynamic cardiovascular risk stratification and monitoring of GLP‑1 RA response in T2D, inform therapy intensification decisions, and be used for trial enrichment—pending prospective implementation and assay standardization.
Key Findings
- Supervised multi-protein plasma score improved MACE discrimination beyond clinical factors in EXSCEL and validated in independent cohorts.
- The proteomic score and top-ranked proteins were modified by GLP‑1 RA therapy; score reductions associated with better cardiovascular outcomes.
3. Ketone Bodies Derived From Medium-Chain Triglycerides Support Brain Metabolism and Function Under Hypoglycemia in Type 1 Diabetes Mellitus.
Combining mechanistic MRS hypoglycemic clamp studies and a small randomized dietary intervention in people with T1D, investigators show that β‑hydroxybutyrate contributes more to brain metabolism in T1D than in controls, and that MCT supplementation raises BHB and improves working memory and regional brain activation during insulin‑induced hypoglycemia without impairing counterregulatory hormones.
Impact: First-in-human mechanistic and randomized dietary evidence that nutritional ketone elevation (via MCT) can preserve cognitive function during hypoglycemia in T1D—offering an immediately actionable adjunctive strategy for high‑risk situations.
Clinical Implications: MCT supplementation could be considered as an adjunctive, short‑term strategy to support cognition before anticipated hypoglycemia‑prone activities in select T1D patients, with attention to ketone monitoring and ketoacidosis risk; larger trials are needed to confirm safety and long‑term benefit.
Key Findings
- Infused BHB contributed more to brain metabolism in T1D than in healthy controls under hypoglycemic clamps.
- Randomized MCT supplementation increased BHB, improved working memory and regional brain activation during hypoglycemia, without blunting counterregulatory hormone responses.